依维莫司诱导的肺炎与转移性肾细胞癌患者良好结局相关
在芬兰赫尔辛基大学医院85例(队列A)和丹麦奥胡斯大学医院148例(队列B)依维莫司治疗的转移性肾细胞癌患者中,CT证实的肺炎与总生存期、无进展生存期和临床获益率改善相关,并在联合分析中与较长总生存期相关。
要点
- 队列A中CT证实的肺炎(29例,34.1%)与总生存期改善相关(24.7个月 vs 8.5个月,P<0.001)。
- 队列B中CT证实的肺炎(29例,19.6%)与总生存期改善相关(12.9个月 vs 6.0个月,P=0.02)。
- 依维莫司诱导的肺炎可能作为依维莫司疗效的生物标志物。
核心结论
- 依维莫司诱导的肺炎与转移性肾细胞癌患者结局改善相关,可能作为依维莫司疗效的生物标志物。
研究设计与样本
- 研究纳入赫尔辛基大学医院85例接受依维莫司治疗的转移性肾细胞癌患者(队列A),并在奥胡斯大学医院148例接受依维莫司治疗的转移性肾细胞癌患者(队列B)中进行验证。
- 采用Kaplan-Meier、Cox回归和逻辑回归分析CT证实的肺炎与结局的相关性。
主要发现
- 队列A中CT证实的肺炎(N=29,34.1%)与总生存期改善相关(24.7个月 vs 8.5个月,P<0.001)、无进展生存期改善相关(5.5个月 vs 3.2个月,P=0.002),临床获益率为57.1% vs 24.1%(P=0.003)。
- 队列A多因素分析中,肺炎与总生存期改善相关(HR 0.22;95%CI 0.12-0.44;P<0.001)、无进展生存期改善相关(HR 0.37;95%CI 0.21-0.66;P=0.001)、临床获益率相关(OR 4.11;95%CI 1.42-11.95;P=0.01)。
- 队列B中CT证实的肺炎(N=29,19.6%)与总生存期改善相关(12.9个月 vs 6.0个月,P=0.02)、无进展生存期改善相关(6.0个月 vs 2.8个月,P=0.02),临床获益率为79.3% vs 39.5%(P<0.001)。
- 队列B多因素分析中,肺炎与总生存期改善相关(HR 0.58;95%CI 0.36-0.94;P=0.03)、无进展生存期改善相关(HR 0.61;95%CI 0.39-0.95;P=0.03)、临床获益率相关(OR 5.65;95%CI 2.10-15.18;P=0.001)。
- 联合多因素分析(N=233)中,以肺炎为时间依赖协变量,CT证实的肺炎与较长总生存期相关(HR 0.67;95%CI 0.46-0.97;P=0.03);里程碑分析中肺炎与较长总生存期相关(17.4个月 vs 7.8个月,P=0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mammalian target of rapamycin inhibitors may induce pneumonitis. We analysed the association of pneumonitis with outcomes in everolimus treated metastatic renal cell carcinoma (mRCC) patients. PATIENTS AND METHODS: Eighty-five mRCC patients received everolimus at Helsinki University Hospital (cohort A). Computed tomography (CT) verified pneumonitis was correlated with outcome using Kaplan-Meier, Cox regression and logistic regression. An independent cohort of 148 everolimus treated mRCC patients (cohort B) at Aarhus University Hospital was assessed for validation. RESULTS: In cohort A, CT-verified pneumonitis (N = 29, 34.1%) was associated with improved overall survival (OS) (24.7 versus 8.5 months; P < 0.001), progression-free survival (PFS) (5.5 versus 3.2 months; P = 0.002) and clinical benefit rate (CBR) 57.1% versus 24.1% (P = 0.003). In multivariate analyses pneumonitis was associated with improved OS (hazard ratio [HR], 0.22; 95% confidence interval [CI] 0.12-0.44; P < 0.001), PFS (HR 0.37; 95% CI 0.21-0.66; P = 0.001) and CBR (odds ratio [OR] 4.11; 95% CI 1.42-11.95; P = 0.01). In cohort B, CT-verified pneumonitis (N = 29, 19.6%) was associated with improved OS (12.9 versus 6.0 months; P = 0.02), PFS (6.0 versus 2.8 months; P = 0.02) and CBR (79.3% versus 39.5%; P < 0.001). In multivariate analyses pneumonitis was associated with improved OS (HR 0.58; 95% CI 0.36-0.94; P = 0.03), PFS (HR 0.61; 95% CI 0.39-0.95; P = 0.03) and CBR (OR 5.65; 95% CI 2.10-15.18; P = 0.001). In a combined multivariate analysis (N = 233), with pneumonitis as a time-dependent covariate, CT-verified pneumonitis was associated with longer OS (HR, 0.67; 95% CI 0.46-0.97; P = 0.03). Furthermore, in a landmark analysis, pneumonitis was associated with longer OS (17.4 versus 7.8 months; P = 0.01). CONCLUSIONS: Everolimus-induced pneumonitis is associated with improved outcome in patients with mRCC and may serve as a biomarker of everolimus efficacy.
引用
- Penttilä P, Donskov F, Rautiola J, et al. Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma. Eur J Cancer. 2017. PMID: 28586749. doi:10.1016/j.ejca.2017.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。